|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | CSD00351 |
| 保存条件 | store at -80℃ |
| 用途 | 仅用于科研用途 |
| 应用范围 | |
| 抗原来源 | CHO cells |
| CAS编号 | 1421830-13-8 |
| 保质期 | 一年 |
| 抗体名 | Lulizumab Pegol ( 培戈-鲁利珠单抗 ) |
| 是否单克隆 | |
| 克隆性 | |
| 靶点 | CD28 [Homo sapiens] |
| 适应物种 | |
| 形态 | |
| 宿主 | |
| 标记物 | |
| 包装规格 | 100μg |
| 纯度 | % |
| 亚型 | |
| 标识物 | |
| 浓度 | 95% |
| 免疫原 | |
| 是否进口 | 否 |
Lulizumab pegol is under investigation in clinical trial NCT02843659,Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sj鰃ren's Syndrome.
货号（Catalog No.）
CSD00351
通用名INN
Lulizumab Pegol
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Lulizumab pegol is under investigation in clinical trial NCT02843659,Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sj?gren's Syndrome.
别名(Alternative names)
BMS-931699
靶点;物种(Specificity target name;species)
CD28 [Homo sapiens]
种类(Species)
Humanized
受体鉴定(Receptor identification)
V-kappa
化学信息
CAS
1421830-13-8
存储条件(Storage)
store at -80°C
